AKT1 and lung carcinoma: ZQD and AS-IV reduce MMP2 and MMP9 expression via the PI3K/Akt/p53 and PKC-α–ERK1/2–NF-κB pathways, respectively, thereby inhibiting ECM breakdown and lung cancer cell invasion (56, 57).